Icosagen (company)

Icosagen (formerly Quattromed AS) is an Estonian biotechnology companies providing custom research programs and services to the Biopharmaceutical industry, including antibody discovery, protein production, and GMP manufacturing.

Antibody discovery, development and production, particularly in targeting challenging membrane proteins such as G protein-coupled receptors (GPCRs) and solute carrier (SLC) transporters are key services.

[7] In February 2023, Icosagen secured an €18 million loan from the European Investment Bank, backed by the InvestEU program, to enhance its R&D capabilities and construct a new cGMP production facility.

[9] In October 2023, Icosagen entered into a multi-target antibody research agreement with Salipro Biotech to advance drug discovery programs against challenging membrane proteins, including G protein-coupled receptors (GPCRs) and solute carrier (SLC) transporters.

[12] In July 2024, research involving Icosagen demonstrated that anti-SARS-CoV-2 antibodies in a nasal spray efficiently blocked viral transmission between Ferrets, indicating potential for preventing COVID-19 spread.